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Abstract
Reactive oxygen species produced during the innate immune response to LPS are important agents of anti-pathogen
defence but may also cause oxidative lung damage. Glutathione peroxidase-1 (gpx-1) is an anti-oxidant enzyme that may
protect lungs from such damage. We assessed the in vivo importance of gpx-1 in LPS-induced lung inflammation. Male wild-
type (WT) or gpx-1 deficient (gpx-1
2/2) mice were treated intranasally with PBS or 10 mg LPS and killed 3 and 24 h post LPS.
Lungs were lavaged with PBS and then harvested for inflammatory marker expression. LPS caused an intense neutrophilia in
WT BALF evident 3 and 24 h post challenge that was reduced in gpx-1
2/2 mice. In addition, LPS-treated gpx-1
2/2 mice had
significantly fewer macrophages than LPS-treated WT mice. To understand the basis for this paradoxical reduction we
assessed inflammatory cytokines and proteases at protein and transcript levels. MMP-9 expression and net gelatinase
activity in BALF of gpx-1
2/2 mice treated with LPS for 3 and 24 h was no different to that found in LPS-treated WT mice.
BALF from LPS-treated gpx-1
2/2 mice (3 h) had less TNF-a, MIP-2 and GM-CSF protein than LPS-treated WT mice. In
contrast, LPS-induced increases in TNF-a, MIP-2 and GM-CSF mRNA expression in WT mice were similar to those observed in
gpx-1
2/2 mice. These attenuated protein levels were unexpectedly not mirrored by reduced mRNA transcripts but were
associated with increased 20S proteasome expression. Thus, these data suggest that gpx-1 primes pro-inflammatory
cytokine production after LPS challenge in vivo.
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Introduction
The innate immune response is critical for host defence by
detecting and removing invading pathogens. Inhaled airborne
pathogens are normally sensed by pathogen recognition receptors
predominantly expressed on the respiratory epithelium and
macrophages which in turn coordinate host defence mediated by
proteolytic, cellular and oxidative stress mechanisms [1]. LPS is an
endotoxin from the outer membrane of gram-negative organisms
and a primary trigger of innate immunity and acute inflammation,
which are essential for successful antimicrobial defence reactions
against such organisms [1]. In many cell types, LPS induces
inflammation by binding to soluble LPS-binding protein, which
then facilitates binding to membrane-associated accessory proteins,
particularly membrane CD14 (mCD14) and MD-2 and at least one
signalling-competent co-receptor where mammalian Toll-like
receptor-4 (TLR-4) has been implicated [1]. LPS triggers activation
of myeloid differentiation protein (MyD88), MyD88-associated
protein Mal, TNF-receptor-associated factor-6 (TRAF-6), IL-1-
receptor-associated kinase (IRAK), NF-kB, and Akt [1]. These
signal transduction intermediary molecules in turn up-regulate and
promote the production of inflammatory cytokines such as TNFa,
IL-1b, neutrophil-recruiting chemokines, oxygen radicals and
proteases which are part of the inflammatory defence reaction [1].
Inhaled LPS is an important cause of environmentally induced
airway disease in occupations where exposure to bacteria-
contaminated organic dusts (bioaerosols) is common [2]. In
human volunteers and in several animal species, lung aerosol
challenge or LPS instillation causes a neutrophil-rich inflamma-
tory response [3,4,5]. LPS is released from pathogens such as
Moxarella cataraliss, Haemophilius influenzii and Pseudomonas aeruginosa,
which are known to acutely infect and also to colonize the lungs of
patients suffering from asthma, COPD and cystic fibrosis [6,7,8].
LPS from these organisms has therefore been implicated in
worsening airway inflammation and non-viral exacerbations of
these conditions [4,6]. In addition, environmental exposure to
LPS-containing bio-aerosols was identified as actually causing as
well as exacerbating asthma [6,9,10]. Therefore, understanding
the regulation of inflammation triggered by delivering LPS into
lungs is likely to be relevant to both enhancing host defense in
gram-negative lung infections and dampening detrimental inflam-
mation in some chronic lung diseases or their exacerbations.
Reactive oxygen species (ROS) are a family of highly reactive
molecules that are produced by a variety of cell types in the lung in
response to chemical and physical agents in the environment [11]. It
is well known that ROS are critical in host defence as they kill
invading pathogens. However, their excessive accumulation, or their
impaired clearance, inthe lung results inoxidative damageincluding
DNA damage, lipid peroxidation and protein denaturation [11].
The cell has developed enzymatic defences to combat excessive
production of ROS, including glutathione peroxidase (gpx).
Glutathione peroxidases are a family of selenium-dependent
and independent antioxidant enzymes which catalyze the
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33172reduction of damaging hydrogen peroxide (H2O2) as well as a
large variety of hydroperoxides (such as DNA peroxides and lipid
peroxides) into water and alcohols, respectively, and thus protect
bio-membranes and cellular components against oxidative stress
[12]. Analysis of the selenoproteome has identified six gpx
isoforms in mammals. The cytosolic selenium-dependent gpx-1
is the predominant isoform of cellular gpx and is ubiquitously
expressed throughout the body [12]. Sources in the lungs include
epithelium, alveolar epithelial lining fluid and alveolar macro-
phages [13]. We have previously shown that mice lacking the gpx-
1 gene are highly susceptible to oxidative-stress and have proposed
that gpx-1 may be an attractive target for increasing the anti-
oxidant capacity in ischemia/reperfusion brain injury [14,15,16]
and cigarette smoke-induced lung inflammation [17].
Given that the known biology of gpx-1 appears to be protection
during oxidative stress we proposed that gpx-1 protects against
LPS-induced lung inflammation. Paradoxically, gpx-1 deficient
mice exposed to LPS had significantly reduced levels of BALF
macrophages, neutrophils, TNF-a, MIP-2 and GM-CSF protein.
In contrast, LPS-induced increases in TNF-a, MIP-2 and GM-
CSF mRNA expression in WT mice were similar to those
observed in gpx-1
2/2 mice. Thus, these attenuated protein levels
were unexpectedly not mirrored by reduced mRNA transcripts
but were associated with increased 20S proteasome expression.
Whole lung MMP-9 mRNA, MMP-9 expression, and net
gelatinase activity in BALF of gpx-1
2/2 mice treated with LPS
for 3 and 24 h was no different to that found in LPS-treated WT
mice. Our data provide new evidence for the role of gpx-1 in LPS-
induced lung inflammation and suggest that gpx-1 primes pro-
inflammatory cytokine production after LPS challenge in vivo.
Results
LPS-induced BALF inflammation is reduced in gpx1
2/2
mice
WT mice treated with 10 mg LPS for 3 h had significantly more
BALF cellularity compared to mice treated with PBS (P,0.001,
Figure 1A–C). Differential cell count analysis determined that
there was a significant increase in the number of neutrophils but
no change in macrophage cell number (P,0.001, Figure 1A–C).
However, gpx-1
2/2 mice had significantly fewer numbers of total
cells, macrophages and neutrophils (P,0.001). Total cells,
macrophages and neutrophil numbers in gpx-1
2/2 mice treated
with PBS were similar to those in WT mice treated with PBS
(Figure 1A–C).
WT mice treated with 10 mg LPS for 24 h had significantly
more BALF cellularity compared to mice treated with PBS
(P,0.001, Figure 1D–F). Differential cell count analysis deter-
mined that there was a marked increase in the number of
neutrophils and macrophages. However, gpx-1
2/2 had signifi-
cantly fewer numbers of total cells, macrophages and neutrophils
(P,0.001). Total cells, macrophages and neutrophil numbers in
gpx-1
2/2 mice treated with PBS were similar to those in WT mice
treated with PBS.
LPS-induced increases in MMP-9 expression and net
gelatinase activity are not affected by gpx-1 deletion
Since MMPs contribute to the movement of neutrophils and
macrophages into the lung parenchyma and MMP-9 expression in
response to LPS is transcriptionally regulated by NFkB and AP-1,
we measured the secretion of MMP-9 in the BALF of LPS-treated
mice by gelatin zymography. There was a marked increase in
MMP-9 expression in BALF from WT mice treated with LPS for 3
and 24 h (Figure 2). Consistent with the zymography, there was an
increase in net gelatinase activity in the BALF from mice treated
with LPS for 3 and 24 h (Figure 3). However, gpx-1
2/2 mice
treated with LPS for 3 and 24 h had similar levels of MMP-9 and
net gelatinase activity to LPS-treated WT mice (Figures 2 and 3).
LPS-induced increases in BALF TNF-a, MIP-2 and GM-CSF
protein are reduced in gpx-1
2/2 mice
The levels of pro-inflammatory cytokine (TNF-a), chemokine
(MIP-2), and leukocyte survival factor (GM-CSF) protein in
response to LPS was investigated in WT and gpx-1
2/2 mice
treated with LPS for 3 and 24 h (Figure 4). WT mice treated with
LPS for 3 h had significantly more TNF-a, MIP-2 and GM-CSF
protein as measured by ELISA in BALF compared to PBS-treated
mice (P,0.001) (Figure 4). However, gpx-1
2/2 mice had
significantly reduced levels of TNF-a, MIP-2 and GM-CSF
protein (P,0.05). The levels of TNF-a, GM-CSF and MIP-2 in
BALF of LPS-treated WT and gpx-1
2/2 mice were markedly
lower at the 24 h time-point, and no differences in MIP-2 and
GM-CSF could be detected. However, LPS-treated gpx-1
2/2
mice had significantly less TNF-a than LPS-treated WT mice
(P,0.05).
LPS-induced increases in whole lung TNF-a, MIP-2, GM-
CSF and MMP-9 mRNA are not reduced in gpx1
2/2 mice
The expression of TNF-a, MIP-2, GM-CSF and MMP-9
mRNA in response to LPS was investigated in WT and gpx-1
2/2
mice treated with LPS for 3 and 24 h (Figure 5). LPS treatment of
WT mice caused a significant increase in mRNAs for TNF-a,
MIP-2, GM-CSF and MMP-9 (P,0.001) at both time-points.
Gpx-1 deletion did not affect LPS-induced increases in MIP-2 and
GM-CSF but enhanced MMP-9 and TNF-a mRNA expression at
3 h and 24 h, respectively.
The ubiquitin-proteasome pathway is increased in LPS-
treated gpx-1
2/2 mice
The ubiquitin-proteasome system is the major non-lysosomal
system for the degradation of short half-life proteins that are
involved in basic cellular processes, such as cell-cycle regulation
and apoptosis, transcriptional regulation or antigen processing.
The proteasome is a multicatalytic proteinase complex that is
involved in the selective degradation of proteins. The 20S
proteasome is the proteolytic core particle of a large protein
degradation complex, the 26S proteasome. In order to explore
whether the reduction in BALF TNF-a, MIP-2 and GM-CSF
protein observed in LPS-treated gpx-1
2/2 mice at 3 hours was
associated with the ubiquitin-proteasome pathway we measured
BALF 20S proteasome concentrations (Figure 6). LPS treatment of
WT mice caused a decrease in 20S proteasome levels compared to
PBS-treated WT mice. In contrast, LPS-treated gpx-1
2/2 mice
displayed a 2-fold increase in 20S proteasome levels compared to
PBS-treated gpx-1
2/2 mice. Levels of 20S proteasome in PBS-
treated gpx-1
2/2 mice were similar to those of PBS-treated WT
mice.
Discussion
The principle objective of this study was to investigate the role
of gpx-1 in a mouse model of LPS-induced lung inflammation.
Given that the known biology of gpx-1 appears to be protection
during oxidative stress-induced lung inflammation [14,15,16,17]
we were surprised to find that gpx-1
2/2 mice exposed to LPS have
reduced BALF inflammation, suggesting that gpx-1 exacerbates
LPS-induced lung inflammation in vivo.
Gpx-1 and LPS-Induced Lung Inflammation
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induced lung inflammation in gpx-1 deficient mice we assessed
whether key cytokines and chemokines involved in the recruitment
of inflammatory cells in response to LPS were affected. We have
previously shown that macrophages and neutrophils are increased
in response to LPS in mice [18,19] which is consistent with other
lung LPS-exposure models [3,4,20]. LPS can increase cell
numbers by promoting cell proliferation, recruitment from the
circulation or prolonged survival in the airways. The observed
numbers of BALF macrophages increased by LPS exposure in
mice has been postulated as representatives of both the progeny of
resident alveolar macrophages and influx of blood monocytes
adopting macrophage-like morphology (‘‘alveolar monocytes’’)
[21]. We have previously published that LPS-treated mice had an
increased percentage of BAL macrophages in mitosis compared
with PBS-treated mice based on nuclear mitotic figures indicating
active cell division [18]. Moreover, the increase in BALF
neutrophils in response to LPS is in accordance with whole lung
gene up-regulation of the chemotactic factor MIP-2. The blood
growth factor GM-CSF (a cytokine produced readily by the
respiratory epithelium which regulates the activation and survival
of macrophages and potently increases neutrophil survival and
activation) was also up-regulated. It was interesting to note that the
reduced infiltration of macrophages and neutrophils in BALF of
gpx-1
2/2 mice is in accordance with a reduction in BALF
concentrations of the pro-inflammatory cytokine TNF-a, the
chemotactic factor MIP-2 and the macrophage survival factor
GM-CSF. In addition, gpx-1
2/2 mice treated with LPS for 24 h
had markedly less MCP-1 (major monocyte chemotactic factor)
mRNA expression than LPS-treated WT mice (9065 fold change
relative to 18S and 247651, respectively). What was surprising
was that these attenuated protein levels were unexpectedly not
Figure 1. Effect of LPS on BALF cellularity in WT and gpx-1
2/2 mice. Mice were treated with PBS or LPS (10 mg/mouse) for 3 h (Panels A–C)
and 24 h (Panels D–E) and the number of total cells, neutrophils and macrophages counted. Data are shown as mean 6 SEM for 6 mice per treatment
group. Clear bars represent PBS-treated mice and black bars represent LPS-treated mice. *P,0.001 vs PBS (ANOVA and Bonferroni’s post hoc test),
{
P,0.001 vs WT (for total cells and neutrophils, ANOVA followed by Bonferroni’s post hoc test),
{ P,0.05 vs WT (for macrophages, ANOVA followed by
Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0033172.g001
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2/2
mice. However, from our study it appears that the reduction in
BALF TNF-a, MIP-2 and GM-CSF protein observed in LPS-
treated gpx-1
2/2 mice at 3 hours was due to protein degradation
via the ubiquitin-proteosome pathway. This is consistent with gpx-
1 being able to downregulate 20S proteasome activity [22].
TNF-a is considered to be a key inflammatory mediator in lung
pathology, and its levels are elevated in lung diseases where LPS is
implicated and neutrophilic inflammation is prominent. TNF-a is
released by activated alveolar macrophages in response to LPS
and is a potent chemoattractant for neutrophils. In concert with
chemokines, TNF-a also promotes release of reactive oxygen
species, elastase, and other proteases including MMPs that are
implicated in lung tissue damage. In mice, neutralization of TNF-
a was previously shown to blunt instilled LPS-induced lung
inflammation [23]. LPS triggers preformed TNF-a release from
mast cells, which is consistent with the very rapid increase in TNF-
a levels in our study, and such TNF-a is a potent stimulus for
secondary induction of chemokines that in turn promote leukocyte
influx and survival. We previously investigated the molecular
pathway(s) that mediates this reinforcement of TNF-a levels in vivo
and in particular demonstrated the GM-CSF-dependent activa-
tion of the transcription factors AP-1 and NFkB in response to
LPS [19].
GM-CSF has pro-inflammatory properties because of its action
on neutrophils and cells of the monocyte macrophage lineage [24]
and directly contributes in NFkB-dependent lung inflammation in
part via activation of the upstream kinase Akt/PKB [19].
Recombinant GM-CSF augments leukocyte leukotriene and
superoxide anion production [25], enhances allergic sensitization
[26], and when selectively over-expressed as a transgenic product
in the rat lung epithelium, GM-CSF promotes inflammation and
fibrosis [27]. In our study, we observed that GM-CSF mRNA was
unaltered in gpx-1
2/2 mice treated with LPS compared with LPS-
treated wild type mice. Interestingly, GM-CSF protein was signi-
ficantly reduced in gpx-1
2/2 mice treated with LPS. However,
given that GM-CSF protein in BALF was not completely
abolished, and because GM-CSF inhibits neutrophil apoptosis
Figure 2. Effect of LPS treatment on MMP-9 expression in BALF
of WT and gpx-1
2/2 mice. WT and gpx-1
2/2 mice were treated with
LPS (10 mg/mouse) for 3 h (Panel A) and 24 h (Panel C) and MMP-9
expression in BALF of individual mice measured by zymogarphy. Panels
A & C show MMP-9 assayed by gelatin zymography under reducing
conditions and Panels B & D are the respective densitometric
measurements. Densitometry data are shown as mean 6 SEM for 5–6
mice per treatment group. Clear bars represent PBS-treated mice and
black bars represent LPS-treated mice. *P,0.05 vs respective PBS-
treated mice (ANOVA and Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0033172.g002
Figure 3. LPS-induced increases in net gelatinase activity is not
affected by gpx-1 deletion. Panels A & B show net free gelatinase
activity in neat BALF from individual mice treated with LPS for 3 and
24 h, respectively. Data are shown as mean 6 SEM for 6 mice per
treatment group. Clear bars represent PBS-treated mice and black bars
represent LPS-treated mice. *P,0.05 vs respective PBS-treated mice
(ANOVA and Bonferroni’s post hoc test), **P,0.01 vs respective PBS-
treated mice (ANOVA and Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0033172.g003
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part to apoptosis. GM-CSF levels are markedly elevated in lung
macrophages and airway epithelium by exposure to LPS in vitro
[28] and GM-CSF acts directly as a survival factor for neutrophils
and macrophages [24]. Some of the associated decline in BALF
macrophage numbers could be due to a similar apoptotic cell
death: we have previously observed GM-CSF sensitive macro-
phage replication that is consistent with the ability of GM-CSF to
induce lung macrophage replication in vitro [29] and the increase
in macrophage numbers observed after targeted GM-CSF over-
expression in the lung [27]. In addition, we have previously shown
that GM-CSF regulates lung innate immunity to LPS through
Akt/Erk activation of NFkB and AP-1 in vivo [19], and that these
responses to LPS are suppressed and reversed by neutralization of
GM-CSF via repression of TLR-4 [18].
Proteases which break down connective tissue components are
released by multiple cell types in the lung, particularly epithelium
and macrophages and, among other functions, contribute to
inflammatory cell infiltration into inflamed lungs [30]. MMP-9
induction was previously associated with the development of
emphysema in lungs exposed to LPS [31,32]. In patients with
emphysema there is an increase in BALF concentrations and
macrophage expression of MMP-9 [33]. Neutrophils can also
secrete MMP-9 which can contribute to tissue destruction [30]. In
the present study, LPS increased MMP-9 protein expression and
net gelatinase activity in BALF of WT mice, correlating to the
higher numbers of macrophages and neutrophils observed. It was
a surprise that gpx-1
2/2 mice exposed to LPS had similar BALF
MMP-9 protein expression and net gelatinase activity given the
reduced numbers of macrophages and neutrophils. In our previous
study we found that MMP-9 protein expression was increased in
gpx-1
2/2 mice during cerebral ischemia-reperfusion injury [34].
However, in the present study we found that MMP-9 transcript
was higher in gpx-1
2/2 mice exposed to LPS compared to WT
LPS-treated mice. These findings suggest that gpx-1 does not have
a role in the control of LPS-induced lung inflammation directed by
the protease MMP-9 in mice.
Reactive oxygen species including superoxide, H2O2,a n d
hydroxyl radical are generated during normal and disease-related
metabolic processes and play an important role in modulating cell
activation and function [11]. Most studies have assumed that
increased generation of ROS result in cellular and organ
dysfunction, however recent data suggest that different ROS may
have distinct effects on cellular activation. For example, superoxide
appears to increase the release of pro-inflammatory cytokines by
neutrophils, whereas elevated intracellular concentrations of H2O2
diminish LPS-induced neutrophil activation and the severity of
acute lung injury [12,35,36,37]. Therefore, therapies that increase
intracellular concentrations of H2O2 might be beneficial in
neutrophil-driven pro-inflammatory conditions, such as acute lung
injury. While we have not measured the levels of intracellular H2O2
in this study, we would expect that gpx-1 deficient mice have
enhanced levels ofH2O2 asthe role ofgpx-1istocatalyseH2O2 into
H2O and O2. Thus, these increased levels of H2O2 may contribute
to the reduced lung inflammation observed in our study.
In summary, the marked suppression of LPS-induced lung
inflammation by gpx-1 deletion that we have described, suggests
that gpx-1 is a key mediator of LPS-induced lung inflammation.
These data suggest that gpx-1 primes pro-inflammatory cytokine
production after LPS challenge in vivo and suggest the possible
Figure 4. LPS-induced increases in BALF TNF-a, MIP-2 and GM-
CSF protein are reduced in gpx-1
2/2 mice. Data are shown as
mean 6 SEM for 6 mice per treatment group. Clear bars represent PBS-
treated mice and black bars represent LPS-treated mice. *P,0.001 vs
respective PBS-treated mice (ANOVA and Bonferroni’s post hoc test),
{ P,0.05 vs WT LPS-treated mice (ANOVA followed by Bonferroni’s post
hoc test).
doi:10.1371/journal.pone.0033172.g004
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high neutrophil and macrophage numbers, protease induction,
and TNF-a, MIP-2 and GM-CSF overproduction are believed to
be central agents in disease pathogenesis. However, strategies that
promote gpx-1 activity should be used with caution and fully
evaluated before clinical acceptance.
Materials and Methods
Animal ethics statement
The experiments described in this manuscript were approved by
the Animal Experimentation Ethics Committee of The University
of Melbourne (AEC Application Numbers 05097, 0810912) and
conducted in compliance with the guidelines of the National
Health and Medical Research Council (NHMRC) of Australia.
Animals
Specific pathogen-free male wild type (C57BL/6, 7–10 weeks)
mice were obtained from the Animal Resource Centre Pty. Ltd.
(Perth, Australia) and gpx-1
2/2 mice (7–10 weeks, C57BL/6
background) were bred at the Department of Pharmacology, The
University of Melbourne. Mice were housed at 20uC on a 12-h
day/night cycle in sterile micro-isolators and fed a standard sterile
diet of Purina mouse chow with water allowed ad libitum.
Figure 5. Effect of LPS on whole lung TNF-a, MIP-2, GM-CSF and MMP-9 mRNA expression in WT and gpx-1
2/2 mice. mRNA expression
for all genes was measured simultaneously under identical conditions using quantitative real-time PCR. Responses are shown as fold change relative
to 18S from 6 individual mice. Clear bars represent WT mice and black bars represent gpx-1
2/2 mice. *P,0.001 vs PBS (ANOVA and Bonferroni’s post
hoc test),
{ P,0.05 vs WT (ANOVA followed by Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0033172.g005
Figure 6. Effect of LPS on 20S proteasome concentrations in
BALF of WT and gpx-1
2/2 mice. WT and gpx-1
2/2 mice were
treated with LPS (10 mg/mouse) for 3 h and 20S proteasome
concentrations measured in BALF. Data are shown as the mean for
BALF pooled from 5–6 individual mice per treatment group. Clear bars
represent PBS-treated mice and black bars represent LPS-treated mice.
doi:10.1371/journal.pone.0033172.g006
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Mice were anaesthetized by methoxyflurane (Medical Develop-
ments International Ltd, Springvale, Victoria, Australia) inhala-
tion and 50 ml of (a) PBS and (b) maximally tolerated dose of LPS
(10 mg of Escherichia Coli serotype 026:B6: Sigma in 50 ml of PBS)
administered intranasally as previously described [18,19]. 3 and
24 h after LPS or PBS treatment mice were killed by an i.p.
overdose of anaesthetic (5.6 mg ketamine/1.12 mg xylazine,
Parnell Laboratories, NSW, Australia) and the lungs lavaged with
PBS as previously published [17,18,19,38,39,40]. The total
number of viable cells in the BALF was determined, cytospins
prepared and cells differentiated by standard morphological
criteria. Whole lungs were cleared of blood via right ventricular
perfusion of the heart with 5 ml of PBS, rapidly excised en bloc,
snap-frozen in liquid nitrogen and stored at 280uC until required.
Protease expression and activity in BALF
Zymography was used to identify the predominant MMP in
BALF based on molecular weight and substrate specificity for
gelatine as previously described [17,19,38,39]. This approach
identified MMP-9 as the predominant gelatine degrading
proteinase in our model system. To further quantify gelatinase
activity in BALF, we utilised a fluorogenic substrate (fluorescence
conjugated gelatine, Life Technologies, Foster City, California,
USA) as previously published [17,19,38,39] that only detects free
MMP-9 that is not complexed to its endogenous inhibitors (eg
TIMPs).
RNA extraction and Quantitative Real-Time PCR
Total RNA was extracted from 15 mg of whole lung tissue from
6 individual mice per treatment group using RNeasy kits (Qiagen,
Valencia, California, USA), reverse transcription with SuperScript
III (Applied Biosystems, Foster City, California, USA) and
triplicate real time PCR reactions with Applied Biosystems pre-
developed assay reagents and 18S rRNA internal control were
done as previously described [17,18,19,38,39,40].
ELISAs
Murine TNF-a, MIP-2 and GM-CSF levels were analyzed
according to the manufacturer’s instructions (R&D Systems,
Minneapolis, Minnesota, USA). In addition, 20S proteosome
concentrations in BALF were measured with a Proteasome ELISA
kit as per the manufacturer’s instructions (Enzo Life Sciences, Ann
Arbor, Michigan, USA).
Statistical analyses
As data were normally distributed, they are presented as
grouped data expressed as mean6standard error of the mean
(s.e.m.); n represents the number of mice. Differences were
determined by two-way analysis of variance (ANOVA) followed by
Bonferroni post hoc test for multiple comparisons, where appropri-
ate. All statistical analyses were performed using GraphPad
Prism
TM for Windows (Version 5.02). Probability levels less than
0.05 (P,0.05) were taken to indicate statistical significance.
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